Patents by Inventor Alexandre Côté

Alexandre Côté has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20170333406
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: August 2, 2017
    Publication date: November 23, 2017
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20170334883
    Abstract: The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 3, 2017
    Publication date: November 23, 2017
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Terry Crawford, Martin Duplessis, Andrew Charles Good, Yves LeBlanc, Steven Magnuson, Christopher G. Nasveschuk, Richard Pastor, Anthony F. Romero, Alexander M. Taylor
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20170312292
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: April 7, 2017
    Publication date: November 2, 2017
    Inventors: Anthony F. Romero, Steven R. Magnuson, Richard Pastor, Vickie Hsiao-Wei Tsui, Jeremy Murray, Terry Crawford, Daniel J. Burdick, Brian K. Albrecht, Alexandre Cote, Alexander M. Taylor, Christopher G. Nasveschuck, Yves LeBlanc, Michael Charles Hewitt, Kwong Wah Lai, Kevin Chen
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20170275289
    Abstract: The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 3, 2017
    Publication date: September 28, 2017
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Terry Crawford, Martin Duplessis, Andrew Charles Good, Yves LeBlanc, Steven Magnuson, Christopher G. Nasveschuk, Richard Pastor, Anthony F. Romero, Alexander M. Taylor
  • Therapeutic compounds and uses thereof
    Patent number: 9763922
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 19, 2017
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • Modulators of methyl modifying enzymes, compositions and uses thereof
    Patent number: 9745305
    Abstract: Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: August 29, 2017
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Andrew Cook, Alexandre Côté, Les A. Dakin, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani
  • TARGET ATTACHMENT SYSTEMS, MAIN FRAME FOR RECEIVING DIFFERENT TARGET ATTACHMENT SYSTEMS AND METHODS OF USING THE SAME
    Publication number: 20160370153
    Abstract: A target system for receiving a target having a target body and target projection extending therefrom. The target system comprises a main frame and a target attachment system. The main frame comprises an elongated target receiving member defining an elongated target receiving member surface and two vertically distant projections extending from the elongated target receiving member surface. The target attachment system comprises pair of target attachment supports adapted for being distantly and concurrently mounted on the projections, each one of the target attachment supports having an opening therethrough. The target attachment supports are mounted as a pair, and are defining a passage defined by their openings, the passage being adapted for receiving the target projection. As a result, the target, when hit on the target body, rotates freely around a rotation axis defined by the passage.
    Type: Application
    Filed: June 16, 2016
    Publication date: December 22, 2016
    Inventors: Etienne CÔTÉ, Alexandre CÔTÉ
  • Bromodomain inhibitors and uses thereof
    Patent number: 9522920
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: December 20, 2016
    Assignee: CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Côté, Victor S. Gehling, Jean-Christophe Harmange, Michael Charles Hewitt, Yves Leblanc, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani
  • USE OF CBP/EP300 BROMODOMAIN INHIBITORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20160317632
    Abstract: The present invention relates to use of CBP/EP300 bromodomain inhibitors for the treatment of cancer.
    Type: Application
    Filed: April 11, 2016
    Publication date: November 3, 2016
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, James Edmund Audia, Steven Bellon, Andrea Cochran, Alexandre Cote, Terry Crawford, Benjamin Fauber, Srimoyee Ghosh, Jean-Christophe Harmange, Georgia Hatzivassiliou, Hariharan Jayaram, Jeong Kim, Jose M. Lora, Steven Magnuson, Ira Mellman, Anthony F. Romero, Alexander M. Taylor, Vickie Tsui
  • TARGET ATTACHMENT SYSTEM, SECONDARY TARGET ATTACHMENT DEVICE AND METHOD OF USING THE SAME
    Publication number: 20160258720
    Abstract: There is provided a target attachment system for attaching a target having an opening therethrough. The target attachment system comprises a support comprising a holding member and a releasable target attachment element. The releasable target attachment element comprises an elongated engagement member and an abutment surface. The elongated engagement member is adapted to be inserted through the target opening and to be releasably fixed to the holding member. The abutment surface is adapted to abut the target towards the support once the engagement member is releasably fixed to the holding member. The proposed system does not have exposed mounting brackets or exposed bolts that may redirect bullet splatter in all directions which is dangerous.
    Type: Application
    Filed: March 7, 2016
    Publication date: September 8, 2016
    Inventors: Etienne CÔTÉ, Alexandre CÔTÉ
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20160158207
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 9, 2016
    Applicants: Genentech, Inc., Constellation Pharmaceuticals, Inc.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • Bromodomain inhibitors and uses thereof
    Patent number: 9328117
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: May 3, 2016
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, Jean-Christophe Harmange, Alexandre Cote, Alexander M. Taylor
  • Bromodomain inhibitors and uses thereof
    Patent number: 9249161
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: February 2, 2016
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Côté, Victor S. Gehling, Jean-Christophe Harmange, Michael Charles Hewitt, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani
  • TREATING TH2-MEDIATED DISEASES BY INHIBITION OF BROMODOMAINS
    Publication number: 20160024504
    Abstract: The invention provides methods for treating Th2 cytokine-mediated diseases by inhibiting bromodomain function.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Applicants: CONSTELLATION PHARMACEUTICALS, INC., GENENTECH, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Terry Crawford, Benjamin Fauber, Hon-Ren Huang, Jose M. Lora, Steven Magnuson, Christopher G. Nasveschuk, Andres Salmeron, Robert J. Sims, III, Alexander M. Taylor
  • MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
    Publication number: 20160009718
    Abstract: Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 14, 2016
    Inventors: Brian K. Albrecht, James Edmund Audia, Andrew Cook, Alexandre Côté, Les A. Dakin, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani
  • BROMODOMAIN INHIBITORS AND USES THEREOF
    Publication number: 20140371206
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: June 24, 2014
    Publication date: December 18, 2014
    Applicant: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Côté, Victor S. Gehling, Jean-Christophe Harmange, Michael Charles Hewitt, Yves Leblanc, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani
  • BROMODOMAIN INHIBITORS AND USES THEREOF
    Publication number: 20140296243
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: June 15, 2012
    Publication date: October 2, 2014
    Applicant: CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Jean-Christophe Harmange, Alexandre Cote, Alexander M. Taylor
  • Bromodomain inhibitors and uses thereof
    Patent number: 8796261
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: August 5, 2014
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James E. Audia, Alexandre Côté, Victor S. Gehling, Jean-Christophe Harmange, Michael C. Hewitt, Yves Leblanc, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani
  • BROMODOMAIN INHIBITORS AND USES THEREOF
    Publication number: 20140005169
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: December 2, 2011
    Publication date: January 2, 2014
    Applicant: CONSTELLATION PHARMACEUTICALS
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Cote, Victor S. Gehling, Jean-Christophe Harmange, Michael Charles Hewitt, Christopher G. Naveschuk, Alexander M. Taylor, Rishi G. Vaswani
  • Methods for preparing dioranozinc compounds
    Patent number: 8492574
    Abstract: There are provided methods for preparing diorganozinc compounds of formula R2Zn. For example, such a method can method comprise reacting together a compound of formula ZnX2 with at least one compound chosen from compounds of formulas RM1T, R2M1, and RM2. R, X, M1, M2, and T can be various different chemical entities. Compounds of formula R2ZnR3, in which R2 and R3 are the same or different, can also prepared in a similar manner.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: July 23, 2013
    Inventors: Andre Charette, Alexandre Cote, Alexandre Lemire